ACADIA Pharmaceuticals Inc ACAD Stock Quotes and Insider News

Insider Chart Past 6 Months

Technical Chart

Filings by transaction date

Apr 08, 2024 (filed on Apr 09, 2024)

Insider Name:

Davis Stephen

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-17,716

Price:

$17.87
Apr 08, 2024 (filed on Apr 09, 2024)

Insider Name:

Davis Stephen

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-8,858

Price:

$17.87
Apr 08, 2024 (filed on Apr 09, 2024)

Insider Name:

Teehan Brendan

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,568

Price:

$17.87
Apr 08, 2024 (filed on Apr 09, 2024)

Insider Name:

Kihara James

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-762

Price:

$17.87
Apr 08, 2024 (filed on Apr 09, 2024)

Insider Name:

Kihara James

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-1,028

Price:

$17.87
Apr 08, 2024 (filed on Apr 09, 2024)

Insider Name:

Schneyer Mark C.

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,716

Price:

$17.87
Apr 07, 2024 (filed on Apr 09, 2024)

Insider Name:

Kihara James

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-1,489

Price:

--
Apr 07, 2024 (filed on Apr 09, 2024)

Insider Name:

Kihara James

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

1,489

Price:

--
Apr 05, 2024 (filed on Apr 09, 2024)

Insider Name:

Davis Stephen

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-34,666

Price:

--
Apr 05, 2024 (filed on Apr 09, 2024)

Insider Name:

Davis Stephen

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-17,333

Price:

--

Filings by filing date

Apr 05, 2024 (filed on Apr 09, 2024)

Insider Name:

Davis Stephen

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-34,666

Price:

--
Apr 05, 2024 (filed on Apr 09, 2024)

Insider Name:

Davis Stephen

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-17,333

Price:

--
Apr 08, 2024 (filed on Apr 09, 2024)

Insider Name:

Davis Stephen

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-17,716

Price:

$17.87
Apr 08, 2024 (filed on Apr 09, 2024)

Insider Name:

Davis Stephen

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-8,858

Price:

$17.87
Apr 05, 2024 (filed on Apr 09, 2024)

Insider Name:

Davis Stephen

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

34,666

Price:

--
Apr 05, 2024 (filed on Apr 09, 2024)

Insider Name:

Davis Stephen

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

17,333

Price:

--
Apr 05, 2024 (filed on Apr 09, 2024)

Insider Name:

Teehan Brendan

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-5,024

Price:

--
Apr 08, 2024 (filed on Apr 09, 2024)

Insider Name:

Teehan Brendan

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

S - Open market or private sale

# or value acquired/disposed of:

-2,568

Price:

$17.87
Apr 05, 2024 (filed on Apr 09, 2024)

Insider Name:

Teehan Brendan

Ownership Type:

Direct Ownership

Securities:

Common Stock

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

5,024

Price:

--
Apr 07, 2024 (filed on Apr 09, 2024)

Insider Name:

Kihara James

Ownership Type:

Direct Ownership

Securities:

Restricted Stock Units

Nature of Transaction:

M - Exercise or conversion exempt under rule 16b-3

# or value acquired/disposed of:

-1,489

Price:

--

News

Biz Brief

Sector: Healthcare	Industry: Biotechnology & Medical Research

See Regulatory Filings on SEC

Company Contact

Address:	12830 El Camino Real, Suite 400 SAN DIEGO CA 92130
Tel:	1-858-5582871
Website:	https://acadia.com
IR:	See website

Key People

Stephen R. Davis Chief Executive Officer, Director	Mark C. Schneyer Chief Financial Officer, Executive Vice President	Brendan P. Teehan Chief Operating Officer, Executive Vice President, Head of Commercial
Elizabeth H. Z. Thompson Executive Vice President and Head of Research and Development	Douglas J. Williamson Executive Vice President - Research and Development	Albert Kildani Senior Vice President, Investor Relations and Corporate Communications
Kevin R. Oliver Senior Vice President, Chief Business Officer

Business Overview

Acadia Pharmaceuticals Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has a portfolio of commercial stage products, in-development product opportunities, and research programs that are designed to address unmet needs in CNS disorders and rare diseases. Its pipeline includes NUPLAZID (pimavanserin), DAYBUE (trofinetide), ACP-101, ACP-204, and Antisense Oligonucleotide (ASO) Programs. NUPLAZID is a selective serotonin inverse agonist/antagonist preferentially targeting the 5-HT2A receptor. NUPLAZID is developed for the treatment for Parkinson's Disease Psychosis. Trofinetide is a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 (IGF-1) designed to treat the core symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function.

Financial Overview

For the fiscal year ended 31 December 2023, ACADIA Pharmaceuticals Inc revenues increased 40% to $726.4M. Net loss decreased 72% to $61.3M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest Income, net increase from $6.6M to $17.2M (income), Stock-Based Compensation in R&D decrease of 23% to $17.4M (expense).

Employees:	597 as of Dec 31, 2023

Reporting Currency:	U.S. Dollars
Enterprise value:	$2,295M as of Dec 31, 2023
Annual revenue (TTM):	$726.44M as of Dec 31, 2023
EBITDA (TTM):	-$67.83M as of Dec 31, 2023
Net annual income (TTM):	-$61.29M as of Dec 31, 2023
Free cash flow (TTM):	$16.65M as of Dec 31, 2023
Net Debt Last Fiscal Year:	N/A
Shares outstanding:	164,771,521 as of Feb 21, 2024
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization